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Abstract
Introduction We have previously observed that Brown Norway
(BN) rats display a relative resistance to experimental
Chlamydia-induced arthritis. In the present study, we examine
an environmental toxin, mercuric chloride (HgCl2), as a
modulator of this innate resistance to arthritis.
Methods To assess the effect of the heavy metal exposure, one
group of rats received two subcutaneous injections of HgCl2 (1
mg/kg) 48 hours apart. Seven days later, the animals received
the intra-articular injection of synoviocyte-packaged Chlamydia.
Results Histopathology revealed that BN rats receiving only
Chlamydia had a minimal cellular infiltration in the joint, which
was predominantly mononuclear in character. In contrast,
mercury-exposed rats had a marked exacerbation of the
histopathological severity of the arthritis, and the infiltration was
predominantly neutrophilic. Mercury exposure was also
associated with marked enhancement in IgE levels and an
alteration in IgG2a/IgG1 ratio, reflecting a Th2 shift. The local
cytokine profile in the joint was markedly altered after mercury
exposure, with a suppression of tumour necrosis factor-alpha
and interferon-gamma but an enhancement of vascular
endothelial growth factor. This was associated with decreased
host clearance capacity reflected in enhanced bacterial load in
both the spleen and the joint and was accompanied by
enhanced detection of microbial antigens in the synovial tissues
by immunohistological staining.
Conclusions Genetically defined cytokine production in the
joint defines the severity of reactive arthritis by dictating the local
clearance of the pathogen. This interplay can be altered
dramatically by heavy metal exposure, which results in
suppression of protective cytokines in the microenvironment of
the joint.
Introduction
Many rheumatic diseases are thought to reflect an interplay of
genetic susceptibility and environmental triggers, but there are
few examples in which strong clues for the nature of these
interacting elements are known. One such example is reactive
arthritis (ReA), in which susceptible individuals develop an
aseptic arthritis following an extra-articular infection. Yet dis-
secting the immune mechanisms in ReA has proven to be dif-
ficult in the clinical setting. Experimental Chlamydia
trachomatis-induced arthritis (CtIA) affords the opportunity to
systematically address the factors that define outcomes after
exposure to this arthritogenic pathogen [1]. We have recently
observed that the Brown Norway (BN) rat is resistant to CtIA
[2], with minimal transient inflammation in the joint. The infiltrat-
ing cell population in the joint is primarily mononuclear in
nature and joint damage is minimal. This contrasts with an
aggressive neutrophilic infiltration with associated joint injury
that is seen in susceptible strains.
In contrast to their inherent resistance to this arthritis, BN rats
are uniquely susceptible to the development of a variety of
autoimmune conditions mediated mainly through Th2 mecha-
nisms [3]. One such condition is the development of autoim-
munity subsequent to an exposure of mercury [4]. The
hallmarks of this condition are the increase of circulating IgE,
the overproduction of interleukin-4 (IL-4), and the activation of
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Th2 cells [5,6]. The normal CD4/CD8 balance and their asso-
ciated cytokines are markedly disrupted [7]. This is accompa-
nied by the appearance of a range of autoantibodies [5,8,9].
Early pivotal studies examining the effects of mercuric chloride
(HgCl2) in rats documented a significant increase in total IgE
and this was observed in BN rats but not in Lewis rats [10].
Subsequent studies revealed that HgCl2 induction of IL-4 was
accompanied by a decrease in CD23 expression on B cells
and that IL-2, IL-6, and IL-10 were upregulated as well as IL-4
following HgCl2 exposure in BN rats [11,12]. Because the BN
rat displays a dichotomy of resistance to infection-triggered
arthritis but susceptibility to mercury-induced immune disrup-
tion, we addressed how these factors would interact if they
were temporally related in the rat.
Materials and methods
Animals
Eight week-old male BN rats were purchased from Harlan Lab-
oratories, Inc. (Indianapolis, IN, USA). The animals were main-
tained in microisolators under specific pathogen-free
conditions in the animal care facility of the Toronto Western
Hospital. All animals studied were less than 12 weeks of age.
The studies were conducted with the approval of the Animal
Care Committee of the University Health Network.
Induction of arthritis
Chlamydia trachomatis-induced arthritis
Arthritis was induced in the rats by intra-articular injection of
synoviocyte-packaged Chlamydia as described [2]. Briefly, C.
trachomatis serotype L2 was inoculated onto monolayers of
rat synovial fibroblasts (SFs) in tissue culture. These stable SF
lines were developed as described [1]. After overnight incuba-
tion, cells were harvested and adjusted to 5 × 10 PP5PP/mL.
Rats were anaesthetized with isoflurane (Pharmaceutical Part-
ners of Canada, Richmond Hill, ON, Canada), and 0.2 mL of
the infected cells containing 2 × 10 PP5PP colony-forming
units (CFU) of Chlamydia was injected into the knee joint. Joint
swelling was measured with a caliper and recorded in millime-
tres. Animals were euthanized at day 7 post-injection. Mock
injections on non-infected synoviocytes had previously been
shown to induce only a transient inflammation in the joint.
Protocol and injection schedule for HgCl2
Several different dose schedules have been used previously
by investigators to address response to HgCl2 [5,6,8,9]. Roos
and colleagues [13,14] used a two-injection abbreviated
schedule to investigate the short-term effects of HgCl2 expo-
sure. This protocol was associated with less morbidity than
other protocols using five injections over a 10-day period.
These investigators observed that distinctive immunological
changes were rapid and were observed as early as 4 days
after the initial HgCl2 exposure, with minimal toxicity. We there-
fore adopted the two-injection protocol of Roos and col-
leagues [13,14]. HgCl2 (Sigma-Aldrich, St. Louis, MO, USA)
was dissolved in water at 1 mg/mL and then filter-sterilized.
The rats were anaesthetized by inhalation using isoflurane,
weighed, and injected with the HgCl2 solution subcutaneously
at a dosage of 1 mg/kg of body weight. Two days later, the
injection procedure was repeated. The animals tolerated this
procedure well, with no local or systemic adverse effects
noted. There was no joint swelling or joint discomfort noted fol-
lowing the two injections of HgCl2. Seven days after the sec-
ond HgCl2 injection, the rats were anaesthetized again and
synoviocyte-packaged Chlamydia (2 × 105 CFU) was deliv-
ered by intra-articular injection into the knee joint in accord-
ance with our established protocol [2]. Control rats without
antecedent exposure to HgCl2 received a similar intra-articular
injection of synviocyte-packaged Chlamydia. One week after
the injection of the joint, the animals were sacrificed by anaes-
thetic overdose. Eight animals were used for each compara-
tive experimental condition.
Processing and pathology
The knee joints were removed and fixed in formalin. The lateral
width of each joint was measured with a caliper. After meas-
urement, the joints were decalcified and processed for his-
topathological scoring as described [2]. Immunopathology
studies used a primary antibody specific for C. trachomatis
(AbD Serotec, Oxford, Oxfordshire, UK) that was developed
with a peroxidase-conjugated anti-mouse antibody.
Chlamydia quantitation
The Dako IDEIA™ PCE Chlamydia Kit (Dako, Ely, Cambridge-
shire, UK) was used for determining the clearance of the path-
ogen. Seven days after the intra-articular injection of
Chlamydia, the HgCl2-exposed and non-exposed rats were
sacrificed. Spleens were removed and ground over a Falcon
Cell Strainer (BD Biosciences 2280 Argentia Road, Missis-
sauga, ON L5N 6H8, Canada) using the rubber end of a
syringe in a Petri dish containing 10 mL of phosphate-buffered
saline (PBS). The tissue homogenate suspensions were fro-
zen at -70°C until tested. For analysis of synovial tissue, the
injected joints were dissected and the tissues were removed.
Tissues were stored in 1 mL of the transport buffer provided
with the enzyme-linked immunosorbent assay (ELISA) kit and
then were frozen as above.
Serology
Blood was obtained from the rats at sacrifice by cardiac punc-
ture. Sera were separated and frozen at -70°C until used.
Results reflect serological changes 14 days after HgCl2 expo-
sure and 7 days after onset of CtIA.
Total serum IgE
Elevation in serum IgE is the hallmark of Hg-induced autoim-
munity in the BN rat. The ELISA for total serum IgE was per-
formed using an antibody pair kit from AbD Serotec in
accordance with the protocol of the manufacturer. A mouse
anti-rat IgE monoclonal antibody was used to coat the ELISA
plate. All sera were diluted 1:100 and incubated in the wellsAvailable online http://arthritis-research.com/content/11/1/R19
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for 90 minutes. This was followed by the second antibody, per-
oxidase-conjugated anti-rat kappa/lambda, which was used at
a 1:2,000 dilution for a second 90-minute incubation. O-phe-
nylenediamine (Sigma-Aldrich) was used for development,
and the plates were read at 490 nm.
Anti-Chlamydia antibodies
The anti-Chlamydia antibody ELISA followed our published
methods [1]. ELISA plates were coated with a 10-μg/mL prep-
aration of Chlamydia in a pH 9.6 carbonate-bicarbonate buffer
overnight at 4°C. A single batch of plates was prepared and
kept frozen. Rat sera were diluted 1:200 in PBS containing
1% bovine serum albumin (BSA) as blocking agent, and 0.2
mL was added to each well in triplicate. After 90 minutes of
incubation at 37°C, plates were washed and peroxidase-con-
jugated antibodies were added. Peroxidase-conjugated goat
anti-rat IgG1 and IgG2a secondary antibodies were obtained
from Bethyl Laboratories, Inc. (Montgomery, TX, USA) and
used at a 1:10,000 dilution. After a further 90-minute incuba-
tion at 37°C, the plates were washed and colour-developed
with o-phenylenediamine (0.4 mg/mL) as substrate. Plates
were read at 490 nm with an ELISA plate reader.
Anti-collagen(II) antibodies
The ELISA kit for the rat anti-type II collagen antibodies was
from Chondrex (Redmond, WA, USA) and followed the proto-
col of the manufacturer. Rat serum was run at a 1:200 dilution
in the assay.
Cytokines
Serum and synovial tissue cytokine levels in the Hg-exposed
and non-exposed BN rats were assayed as previously
described [2]. Rat interferon-gamma (IFN-γ), tumour necrosis
factor-alpha (TNF-α), IL-4, and IL-10 were assayed by ELISA
kits purchased from Pierce Endogen (Thermo Fisher Scientific
Inc., Rockford, IL, USA). The ELISA for rat vascular endothelial
growth factor (VEGF) was purchased from Bender MedSys-
tems (Vienna, Austria).
Nitric oxide
The kit to determine total nitric oxide (NO) concentrations was
from R&D Systems (Minneapolis, MN, USA) (KGE001). This is
a colorimetric assay using the Griess reaction with the entire
procedure performed on an ELISA plate. The serum samples
are filtered through 10,000-molecular weight cutoff spin filter
units (Millipore Microcon YM-10; Millipore Corporation, Biller-
ica, MA, USA) prior to the assay. Serum samples (0.5 mL in
size) were loaded on top of the filter units and then centrifuged
in Eppendorf centrifuge at a speed of 14,000 rotations per
minute for 30 minutes at room temperature.
Statistical analysis
The Student t test was used to compare statistical differences
between groups.
Results
Acute inflammatory response
After induction of CtIA, a significant difference was observed
between the HgCl2-exposed rats compared with controls. The
rats with a prior exposure to HgCl2 demonstrated significantly
more joint swelling compared with the normally mild swelling
of naïve BN rats using the same injection protocol. The mean
joint width in the HgCl2-exposed rats (n = 8) was 13.7 ± 0.53
mm in comparison with a control joint mean size (n = 8) of 9.6
± 0.86 mm (P < 0.0001) (Figure 1a).
Histologically, two systemic injections of HgCl2 induced no
pathological changes in the joint (Figure 2). The CtIA in the
non-HgCl2-exposed control rats was accompanied by only
modest synovial hypertrophy and hyperplasia (Figure 2). Syn-
ovial tissue cellular infiltration was pleomorphic, with mononu-
clear cells comprising the dominant population. Pannus
formation was minimal and there were only mild changes in
Figure 1
Joint swelling and histopathology scores demonstrating exacerbation of Chlamydia-induced arthritis following a prior systemic exposure to mercuric  chloride (HgCl2) (n = 8 in each group) Joint swelling and histopathology scores demonstrating exacerbation of Chlamydia-induced arthritis following a prior systemic exposure to mercuric 
chloride (HgCl2) (n = 8 in each group). The differences after HgCl2 exposure are significant (P < 0.005) in both joint swelling (a) and histopatholog-
ical severity scores (b). Hg, mercury. Ct, Chlamydia trachomatis.Arthritis Research & Therapy    Vol 11 No 1    Inman and Chiu 
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bone and cartilage. This is the pattern observed in BN rats in
our previous studies [2]. In contrast, the joints of the HgCl2-
exposed rats demonstrated more marked synovial hypertrophy
and hyperplasia (Figure 2). This was accompanied by massive
infiltration of the synovial tissues with a predominance of neu-
trophils. There were areas of necrosis and bone and cartilage
destruction by aggressive pannus formation. The invading
pannus could be seen invading subchondral bone. Thus, the
HgCl2  exposure altered the mild arthritis characteristic of
resistant BN into the aggressive profile of the arthritis charac-
teristic of susceptible rats. When the histopathological scor-
ing system was applied, the joint scores of the HgCl2-exposed
test rats (n = 8) were significantly higher (average score of
99.28% ± 1.89% of maximum) than those of controls (average
score of 58.75% ± 7.44% of maximum) (P < 0.0001) (Figure
1b).
Figure 2
Histopathology (haematoxylin and eosin) in Chlamydia trachomatis-induced arthritis (CtIA) alone and after a prior exposure to mercuric chloride  (HgCl2) Histopathology (haematoxylin and eosin) in Chlamydia trachomatis-induced arthritis (CtIA) alone and after a prior exposure to mercuric chloride 
(HgCl2). CtIA in the non-HgCl2-exposed control rats is accompanied by only moderate synovial hypertrophy and hyperplasia and a mononuclear cell 
infiltration (a-c). Eight animals were studied in each group. The joints of the HgCl2-exposed rats demonstrated more marked synovial hypertrophy 
and hyperplasia and a marked infiltration of the synovial tissues, primarily by neutrophils. This is accompanied by bone and cartilage destruction and 
by pannus formation, which invades subchondral bone (d-f). Panel (g) is representative of a rat that received the HgCl2 injections alone and shows 
no pathological change in the joint. Original magnifications × 200.Available online http://arthritis-research.com/content/11/1/R19
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Serum IgE
There was a dramatic elevation of serum IgE levels (Figure 3)
in HgCl2-exposed animals (1.66 ± 0.05) compared with con-
trols (0.30 ± 0.07), representing a 4.5-fold increase with
HgCl2 exposure (P < 0.0001) (n = 8 in each group).
Anti-Chlamydia antibodies
The HgCl2-exposed rats (n = 8) had significantly higher serum
IgG1 anti-Chlamydia  antibodies (0.26 ± 0.05) than non-
exposed control rats (0.13 ± 0.03) (P < 0.001) (Figure 4a).
On the other hand, the control rats (n = 8) had slightly higher
(P = 0.12) IgG2a anti-Chlamydia antibodies (0.21 ± 0.02)
than the HgCl2-exposed rats (0.18 ± 0.03). The IgG2a to
IgG1 ratio was 1.57 for the control rats in contrast to 0.70 for
the HgCl2-exposed animals, consistent with a shift toward a
Th2 response after HgCl2 exposure.
Anti-collagen(II) antibodies
The HgCl2-exposed BN rats (n = 8) had higher levels of IgG
antibodies to rat type II collagen than did controls: 0.108 ±
0.069 versus 0.032 ± 0.012 (P < 0.01). These serological
changes paralleled the enhanced severity of arthritis clinically
and histologically following HgCl2 exposure (Figure 4b).
Cytokine profiles
After intra-articular injection with Chlamydia, there was an
increase in the serum levels of IFN-γ (n = 4) and TNF-α (n = 4)
(Figure 5a). These were significant increases compared with
normal rat serum for both IFN-γ (P < 0.005) and TNF-α (P <
0.001). There were no significant increases in serum IL-10 or
IL-4 after Chlamydia joint injection (n = 4). Prior HgCl2 expo-
sure was associated with suppression of the expected rise in
serum IFN-γ and TNF-α seen with CtIA. The differences
between the HgCl2-exposed and non-exposed controls were
significant for IFN-γ (P = 0.002) and TNF-α (P = 0.014). No
comparable differences were detected for IL-4 or IL-10, but
the baseline levels were low in both cases. Inflamed synovial
tissues from Chlamydia-injected rats were harvested for
assays for tissue cytokine profiles using the dot-blot method
(Figure 5b). HgCl2 exposure was accompanied by a decrease
in local cytokine production for IFN-γ (P < 0.005), TNF-α (P <
0.05), and IL-1 (P  < 0.05). No significant difference was
observed for synovial IL-10.
Chlamydia clearance
HgCl2-exposed rats demonstrated a relative defect in host
clearance of the pathogen both locally and systemically (n = 5
in each group). The mean level of the splenic bacterial load
(measured in optical density units) for the HgCl2-exposed rats
was 0.092 ± 0.035 in contrast with 0.009 ± 0.003 for the con-
trols (Figure 6a). This clearance difference is statistically sig-
nificant (P < 0.005). In the joint, the average Chlamydia load
for the HgCl2-exposed rats was significantly higher (0.419 ±
0.264) than that of controls (0.028 ± 0.014) (P < 0.05) (Fig-
ure 6b). Immunohistology shows more intense staining with
anti-Chlamydia antibodies in the HgCl2-exposed rats (Figure
6c) than in controls (Figure 6d), reflecting the relative failure of
the HgCl2-exposed rat to achieve local clearance of the path-
ogen.
Nitric oxide and vascular endothelial growth factor
Serum NO was elevated (3.99 ± 0.83 μM) in CtIA compared
with serum from naïve rats (n = 4) (2.08 ± 0.47 μM). HgCl2
alone had no impact on serum NO compared with naïve rats,
but there was an additive effect of Ct and HgCl2 observed
(5.97 ± 1.58 μM; P < 0.001) (Figure 7a). Serum VEGF was
increased by exposure to HgCl2 alone (56.67 ± 20.22 pg/mL)
in comparison with normal rat serum (9.21 ± 3.3 pg/mL), but
Ct alone did not elevate serum VEGF in comparison with nor-
mal rat serum (Figure 7b). In contrast, Ct and HgCl2 had an
additive effect on the serum VEGF (110.56 ± 37.37 pg/mL; P
< 0.001 in comparison with normal rat serum). Four animals
were studied in each group. The elevation in NO and VEGF
was in contrast to some of the cytokine-suppressive effects of
HgCl2 exposure, with serum levels of NO and VEGF rising
more with the combined exposure than to either exposure
alone. This corresponded to the most intense pathological
changes in the joints of animals with dual-exposure to both Ct
and HgCl2.
Discussion
The spondyloarthropathies (SpAs) refer to a group of diseases
that share several common features: association with HLA
class I genes, asymmetric oligoarthritis, axial involvement,
enthesitis, and characteristic extra-articular features such as
uveitis. The role of infection as a triggering factor is implicated
with varying degrees of certainty amongst the SpA subcatego-
Figure 3
The effect of prior exposure to mercuric chloride (HgCl2) on serum IgE  levels in Chlamydia-induced arthritis The effect of prior exposure to mercuric chloride (HgCl2) on serum IgE 
levels in Chlamydia-induced arthritis. The serum IgE levels are signifi-
cantly increased compared with controls (P < 0.0001) (n = 8 in each 
group). O.D., optical density.Arthritis Research & Therapy    Vol 11 No 1    Inman and Chiu 
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ries, with ReA having the most clear evidence for a microbial
trigger [15]. The most direct causal evidence for microbial trig-
gers for ReA derives from a demonstration of microbial anti-
gens in the joint [16]. The case for intra-articular pathogens is
strongest for Chlamydia, and several investigators have used
polymerase chain reaction to demonstrate Chlamydia DNA or
RNA in the joints of patients with post-Chlamydia ReA [17-
19]. There is some evidence that these organisms are meta-
bolically altered and may have entered a quiescent phase
[20,21]. Several studies support the notion of a viable organ-
ism present, at least transiently, in the early stages of ReA. It is
speculated that this may reflect defective killing of the organ-
ism by failure either to internalize the pathogen or to effectively
initiate intracellular killing. There has been particular interest in
the Chlamydia heat shock proteins, notably heat shock protein
60 (hsp60), and recent studies have identified differential
expression of three C. trachomatis hsp60-encoding genes
that may differ in active versus persistent infections [22]. The
cellular response to Chlamydia infection has been studied by
microarray techniques, and 18 genes appeared to be selec-
tively upregulated following infection with C. trachomatis [23].
Profiling Chlamydia infection of U937 monocytic cells [24]
and human lung epithelial cells [25] has provided a profile of
induced gene expression and, in particular, which cytokines
are induced by this microbial challenge.
Analysis of cytokine profiles is a further method for studying
the link between infection and ReA. In a study of 11 patients
Figure 4
The effect of prior exposure to mercuric chloride (HgCl2) on serum anti-Chlamydia antibodies and anti-collagen antibodies in Chlamydia-induced  arthritis The effect of prior exposure to mercuric chloride (HgCl2) on serum anti-Chlamydia antibodies and anti-collagen antibodies in Chlamydia-induced 
arthritis. (a) HgCl2-exposed rats had significantly higher serum IgG1 anti-Chlamydia antibodies than non-exposed control rats (P < 0.001). Control 
rats had slightly higher IgG2a anti-Chlamydia antibodies than the HgCl2-exposed rats (P = 0.12). (b) HgCl2-exposed Brown Norway (BN) rats had 
higher levels of IgG antibodies to rat type II collagen than controls (P < 0.01) (n = 8 in each group). O.D., optical density.
Figure 5
Serum and synovial cytokine profiles Serum and synovial cytokine profiles. (a) Serum cytokines in normal rats and in Chlamydia-induced arthritis alone or after prior exposure to mercuric 
chloride (HgCl2). After the onset of Chlamydia trachomatis-induced arthritis (CtIA), there was a significant increase in the serum levels of interferon-
gamma (IFN-γ) (P < 0.005) and tumour necrosis factor-alpha (TNF-α) (P < 0.001). Prior HgCl2 exposure was associated with significant suppres-
sion of IFN-γ (P = 0.002) and TNF-α (P = 0.014) seen with CtIA. (b) Synovial cytokines in Chlamydia-induced arthritis alone or after prior exposure 
to HgCl2. HgCl2 exposure was accompanied by a decrease in local cytokine production for IFN-γ (P < 0.005), TNF-α (P < 0.05), and interleukin (IL)-
1 (P < 0.05) compared with controls. No significant difference was observed for synovial IL-10 (n = 4 in each group).Available online http://arthritis-research.com/content/11/1/R19
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with ReA, it was observed that stimulation of SF mononuclear
cells resulted in secretion of low amounts of IFN-γ and TNF-α
but high amounts of IL-10 [26]. IL-10 was responsible for sup-
pression of IFN-γ and TNF-α as judged by the effect of adding
IL-10 or anti-IL-10 to the cells. The suppression of Th1-like
cytokines is likely mediated through suppression of IL-12 syn-
thesis. This IL-10/IL-12 balance, resulting in a predominance
of Th2 cytokines, may contribute to the persistence of bacteria
in the joint. In comparison with rheumatoid arthritis, SF levels
of TNF-α in ReA are lower despite comparable levels of IL-2
receptor, again implicating a relative deficiency of protective
antimicrobial cytokines in the local environment [27]. Analysis
of synovial fluid cytokines has been studied in patients with
Chlamydia-induced arthritis and it was found that B27+
patients had lower SF IFN-γ levels and it was these patients
who had a more chronic course [28]. This suggests that dimin-
ished IFN-γ generation might account for the persistence of
the arthritis.
Our previous studies in experimental ReA have paralleled
these clinical findings. BN rats that are relatively resistant to
CtIA exhibit an enhanced IFN-γ and TNF-α expression in the
microenvironment of the joint. This is accompanied by
enhanced clearance of the pathogen and a more transient and
benign course of the arthritis. In the present study, we have
found that this inherent resistance to ReA can be overcome by
heavy metal exposure. Mercury exposure alters the cytokine
profile, host clearance capability, and histopathological out-
come from the resistant phenotype to the susceptible pheno-
type. Our findings contrast with the experience studying
murine collagen-induced arthritis, in which prior exposure to
HgCl2 did not influence the outcome of the arthritis, but expo-
sure following the onset did have an aggravating effect on the
arthritis [29].
If HgCl2 diminishes protective cytokines in the microenviron-
ment of the joint, what is driving the aggressive inflammation
and subsequent joint damage? Our study suggests that NO
and VEGF are two important candidates. We have previously
studied NO contribution to clearance of arthritogenic patho-
gens by synoviocytes and observed that in some instances
there was an IFN-γ-mediated suppression of NO in such cells,
Figure 6
Host clearance of Chlamydia from the spleen and the joint Host clearance of Chlamydia from the spleen and the joint. Tissues were harvested 5 days after the induction of Chlamydia trachomatis-induced 
arthritis (CtIA). (a) The mean level of the splenic bacterial load for the mercuric chloride (HgCl2)-exposed rats was higher than that of controls (P < 
0.005). (b) In the joint, the mean Chlamydia load for the HgCl2-exposed rats was significantly higher than that of controls (P < 0.05). Immunohistol-
ogy shows more intense staining with anti-Chlamydia antibodies in the HgCl2-exposed rats (c) than controls (d) (n = 5 in each group). Original mag-
nifications × 200. O.D., optical density.Arthritis Research & Therapy    Vol 11 No 1    Inman and Chiu 
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suggesting a dynamic interaction between these two factors
[30]. This interaction may be specific to the cells under inves-
tigation since, in the case of J774 macrophages, IFN-γ medi-
ated an increase in NO production, which in turn reduced
viability of C. pneumoniae in the infected cells [31]. In our in
vivo model, the rise in NO was concurrent with an increase in
chlamydial load in the host, suggesting that the increase in NO
was not sufficient to contain an expanded replication profile of
the organism. In this regard, it is interesting to note that, in
murine cells, blockage of NO synthesis only partially rescues
chlamydial growth, suggesting that there are other important
IFN-γ-inducible antichlamydial mechanisms operative [32].
Prior studies on the effect of Hg on NO have yielded varying
results depending on the experimental conditions. Kim and
colleagues [33] found that Hg treatment of a macrophage cell
line results in a drop in NO production upon stimulation with
lipopolysaccharide. However, Huang and colleagues [34] dis-
covered that treatment of mice with Hg resulted in an increase
in serum NO levels. The latter results are very much in parallel
with our finding of an increase of NO following exposure to
HgCl2.
The pathological studies in our rats indicate that the exacerba-
tion of histological severity of the arthritis was accompanied by
a neovascularization process locally. It is known that VEGF
plays a crucial role in angiogenesis. Spondylarthritis is charac-
terized by enthesitis and synovitis, in which new blood vessels
participate in perpetuating the inflammation. Serum analysis
from SpA patients has documented that VEGF levels were sig-
nificantly higher in SpA patients than in controls. In SpA
patients, serum VEGF levels correlated with disease activity
indices as defined by the Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI), erythrocyte sedimentation rate, or C-
reactive protein (CRP). These results suggest that VEGF and
therefore angiogenesis may play a role in SpA pathogenesis
and may serve as a disease activity marker in SpAs [35]. In
keeping with these findings, it has been observed that there is
a significant reduction in serum VEGF levels after the infliximab
treatment of SpA patients and that these changes correlate
with similar reductions in CRP and IL-6 [36]. Direct Chlamy-
dia-endothelial cell interactions are known to mediate induc-
tion of VEGF [37].
Mercury exists in elemental, inorganic, and organic forms. The
general population is exposed primarily to mercury vapour
from dental amalgam and to organic mercury from fish con-
sumption [38]. Mercury accumulates in the food chain such
that large fish such as tuna and swordfish have high concen-
trations of mercury in tissues [39]. Occupational exposure is
primarily to mercury vapour and occurs in dentistry, mining,
and the manufacture of electrical equipment. Mercury vapour
is well absorbed through the respiratory tract, but absorption
of elemental mercury is negligible orally whereas oral absorp-
tion of organic mercury is nearly complete [40]. There is recent
evidence from studies of human peripheral mononuclear cells
that low-dose exposure to mercury can polarize the immune
response toward Th2 [41].
The role of mercury in rheumatic diseases has received little
attention. One recent study implicated mercury exposure as a
risk factor for Wegener granulomatosis [42], but the mecha-
nism whereby mercury exposure could alter immune response
and set the stage for chronic inflammatory conditions has not
been resolved. Our experimental system demonstrates that
genetic susceptibility can be fundamentally altered by a heavy
Figure 7
Serum nitric oxide and VEGF profiles Serum nitric oxide and VEGF profiles. Serum nitric oxide (NO) levels (a) and vascular endothelial growth factor (VEGF) levels (b) with the local expo-
sure to Chlamydia trachomatis (Ct) or a systemic exposure to HgCl2 (Hg) or both (Ct + Hg) in contrast to normal rat serum. For both NO and VEGF, 
the increment seen with dual-exposure to Ct and HgCl2 was statistically greater than that seen with either Ct or HgCl2 alone (n = 4 in each group). 
HgCl2, mercuric chloride.Available online http://arthritis-research.com/content/11/1/R19
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metal exposure. This suggests that several environmental fac-
tors may act in concert in the pathogenesis of ReA. The imme-
diate precipitating factor may be a bacterial infection, but this
occurs in the context of other factors in the environment which
influence the immune repertoire. The plasticity of the immune
response, even when encoded in its basic elements by herita-
ble factors, is highlighted in this genetic-environment interac-
tion. As significant advances in the genetic basis of rheumatic
diseases are being made, it will be a challenge to address the
environmental factors with equal rigour.
Conclusion
Genetically defined cytokine production in the joint defines the
severity of ReA by dictating the local clearance of the patho-
gen. This interplay can be dramatically altered by heavy metal
exposure, which results in suppression of protective cytokines
in the microenvironment of the joint.
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